Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.Sumanta Kumar Pal, Laurence Albigès, Mike Roy et al.|Journal of Clinical Oncology|2024Cited by 9